Viatris Inc. (VTRS) Net Profit Margin: -2.04%
Is Viatris Inc.’s net profit margin high or low?
Viatris Inc.'s net profit margin of -2.04% is 57% above its 5-year average of -4.74%, around the middle of its 5-year range (-24.58%–12.78%).
As of Sunday, June 21, 2026. 85.87% above its 12-month average of -14.44%.
VTRS Net Profit Margin Chart
VTRS Average Net Profit Margin Chart
VTRS Current vs Average Net Profit Margin Chart
VTRS Net Profit Margin Metrics
NET PROFIT MARGIN
-2.04%
NET PROFIT MARGIN AVG TTM
-14.44%
NET PROFIT MARGIN AVG 3Y
-3.94%
NET PROFIT MARGIN AVG 5Y
-4.74%
NET PROFIT MARGIN AVG 10Y
-1.51%
NET PROFIT MARGIN AVG 15Y
4.27%
NET PROFIT MARGIN AVG 20Y
4.42%
CURRENT VS TTM AVG
+85.87%
CURRENT VS 3Y AVG
+48.19%
CURRENT VS 5Y AVG
+56.99%
CURRENT VS 10Y AVG
-35.46%
CURRENT VS 15Y AVG
-147.74%
CURRENT VS 20Y AVG
-146.17%
VTRS Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $17.90B | -2.04% | -14.44% | -3.94% | -4.74% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 9.05% | 10.17% | 9.38% | 6.86% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| Incyte Corporation (INCY)vs › | $19.62B | 26.71% | 12.90% | 13.00% | 12.11% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 6.66% | 6.01% | 6.56% | 9.24% |
| DaVita Inc. (DVA)vs › | $13.34B | 5.65% | 6.39% | 5.83% | 6.41% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 17.19% | 18.50% | 17.20% | 16.74% |
| Solventum Corporation (SOLV)vs › | $13.06B | 17.33% | 12.25% | 14.36% | 15.15% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 10.50% | 10.36% | 10.48% | 22.21% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 40.61% | 41.73% | 40.84% | 37.71% |
Margin Comparison
Operating Margin
1.0%
Net Profit Margin
-2.0%
Viatris Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Net Profit Margin FAQ
- What is the net profit margin for Viatris Inc. (VTRS)?
- The net profit margin for VTRS stock is -2.04%.
- Is Viatris Inc.'s net profit margin high or low?
- Viatris Inc.'s net profit margin of -2.04% is 57% above its 5-year average of -4.74%, around the middle of its 5-year range (-24.58%–12.78%).
- What is the TTM average net profit margin for Viatris Inc. (VTRS)?
- The TTM average net profit margin for VTRS stock is -14.44%.
- What is the 3Y average net profit margin for Viatris Inc. (VTRS)?
- The 3Y average net profit margin for VTRS stock is -3.94%.
- What is the 5Y average net profit margin for Viatris Inc. (VTRS)?
- The 5Y average net profit margin for VTRS stock is -4.74%.
- What is the 10Y average net profit margin for Viatris Inc. (VTRS)?
- The 10Y average net profit margin for VTRS stock is -1.51%.
- What is the 15Y average net profit margin for Viatris Inc. (VTRS)?
- The 15Y average net profit margin for VTRS stock is 4.27%.
- What is the 20Y average net profit margin for Viatris Inc. (VTRS)?
- The 20Y average net profit margin for VTRS stock is 4.42%.
Viatris Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -24.58% |
| 2024-12-31 | -4.30% |
| 2023-12-31 | 0.35% |
| 2022-12-31 | 12.78% |
| 2021-12-31 | -7.10% |
| 2020-12-31 | -5.61% |
| 2019-12-31 | 0.15% |
| 2018-12-30 | 3.08% |
| 2017-12-30 | 5.84% |
| 2016-12-30 | 4.33% |
| 2015-12-30 | 8.99% |
| 2014-12-30 | 12.04% |
| 2013-12-30 | 9.03% |
| 2012-12-31 | 9.43% |
| 2011-12-31 | 8.76% |
| 2010-12-31 | 6.33% |
| 2009-12-31 | 4.57% |
| 2008-12-31 | -3.82% |
| 2007-12-31 | -52.23% |
| 2006-03-31 | 14.68% |
| 2005-03-31 | 16.24% |
| 2004-03-31 | 24.34% |
Related Metrics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith